An initiative to improve clozapine prescribing in New York state

Jay Carruthers, Marleen Radigan, Matthew D. Erlich, Gyojeong Gu, Rui Wang, Eric Y. Frimpong, Susan M. Essock, Mark Olfson, Enrico G. Castillo, Gregory Miller, Lloyd I. Sederer, T. Scott Stroup

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Clozapine remains the only medication approved for treatmentresistant schizophrenia. But underuse is the norm. In 2010, the New York State Office of Mental Health began a multifaceted initiative to promote the evidence-based use of clozapine. From 2009 to 2013, in the absence of a wellfunded pharmaceutical marketing campaign, the proportion of newclozapine trials among all newoutpatient antipsychotic trials increased 40% among adult New York Medicaid recipients with a diagnosis of schizophrenia. The largest gains occurred in state-operated clinics. New York's experience demonstrates the feasibility of making clozapine more accessible to patients who stand to benefit most.

Original languageEnglish (US)
Pages (from-to)369-371
Number of pages3
JournalPsychiatric Services
Volume67
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Clozapine
Schizophrenia
Medicaid
Marketing
Antipsychotic Agents
Mental Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Carruthers, J., Radigan, M., Erlich, M. D., Gu, G., Wang, R., Frimpong, E. Y., ... Stroup, T. S. (2016). An initiative to improve clozapine prescribing in New York state. Psychiatric Services, 67(4), 369-371. https://doi.org/10.1176/appi.ps.201500493

An initiative to improve clozapine prescribing in New York state. / Carruthers, Jay; Radigan, Marleen; Erlich, Matthew D.; Gu, Gyojeong; Wang, Rui; Frimpong, Eric Y.; Essock, Susan M.; Olfson, Mark; Castillo, Enrico G.; Miller, Gregory; Sederer, Lloyd I.; Stroup, T. Scott.

In: Psychiatric Services, Vol. 67, No. 4, 01.04.2016, p. 369-371.

Research output: Contribution to journalArticle

Carruthers, J, Radigan, M, Erlich, MD, Gu, G, Wang, R, Frimpong, EY, Essock, SM, Olfson, M, Castillo, EG, Miller, G, Sederer, LI & Stroup, TS 2016, 'An initiative to improve clozapine prescribing in New York state', Psychiatric Services, vol. 67, no. 4, pp. 369-371. https://doi.org/10.1176/appi.ps.201500493
Carruthers J, Radigan M, Erlich MD, Gu G, Wang R, Frimpong EY et al. An initiative to improve clozapine prescribing in New York state. Psychiatric Services. 2016 Apr 1;67(4):369-371. https://doi.org/10.1176/appi.ps.201500493
Carruthers, Jay ; Radigan, Marleen ; Erlich, Matthew D. ; Gu, Gyojeong ; Wang, Rui ; Frimpong, Eric Y. ; Essock, Susan M. ; Olfson, Mark ; Castillo, Enrico G. ; Miller, Gregory ; Sederer, Lloyd I. ; Stroup, T. Scott. / An initiative to improve clozapine prescribing in New York state. In: Psychiatric Services. 2016 ; Vol. 67, No. 4. pp. 369-371.
@article{d73e0b41264141649fcf1b4e7e6cb966,
title = "An initiative to improve clozapine prescribing in New York state",
abstract = "Clozapine remains the only medication approved for treatmentresistant schizophrenia. But underuse is the norm. In 2010, the New York State Office of Mental Health began a multifaceted initiative to promote the evidence-based use of clozapine. From 2009 to 2013, in the absence of a wellfunded pharmaceutical marketing campaign, the proportion of newclozapine trials among all newoutpatient antipsychotic trials increased 40{\%} among adult New York Medicaid recipients with a diagnosis of schizophrenia. The largest gains occurred in state-operated clinics. New York's experience demonstrates the feasibility of making clozapine more accessible to patients who stand to benefit most.",
author = "Jay Carruthers and Marleen Radigan and Erlich, {Matthew D.} and Gyojeong Gu and Rui Wang and Frimpong, {Eric Y.} and Essock, {Susan M.} and Mark Olfson and Castillo, {Enrico G.} and Gregory Miller and Sederer, {Lloyd I.} and Stroup, {T. Scott}",
year = "2016",
month = "4",
day = "1",
doi = "10.1176/appi.ps.201500493",
language = "English (US)",
volume = "67",
pages = "369--371",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "4",

}

TY - JOUR

T1 - An initiative to improve clozapine prescribing in New York state

AU - Carruthers, Jay

AU - Radigan, Marleen

AU - Erlich, Matthew D.

AU - Gu, Gyojeong

AU - Wang, Rui

AU - Frimpong, Eric Y.

AU - Essock, Susan M.

AU - Olfson, Mark

AU - Castillo, Enrico G.

AU - Miller, Gregory

AU - Sederer, Lloyd I.

AU - Stroup, T. Scott

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Clozapine remains the only medication approved for treatmentresistant schizophrenia. But underuse is the norm. In 2010, the New York State Office of Mental Health began a multifaceted initiative to promote the evidence-based use of clozapine. From 2009 to 2013, in the absence of a wellfunded pharmaceutical marketing campaign, the proportion of newclozapine trials among all newoutpatient antipsychotic trials increased 40% among adult New York Medicaid recipients with a diagnosis of schizophrenia. The largest gains occurred in state-operated clinics. New York's experience demonstrates the feasibility of making clozapine more accessible to patients who stand to benefit most.

AB - Clozapine remains the only medication approved for treatmentresistant schizophrenia. But underuse is the norm. In 2010, the New York State Office of Mental Health began a multifaceted initiative to promote the evidence-based use of clozapine. From 2009 to 2013, in the absence of a wellfunded pharmaceutical marketing campaign, the proportion of newclozapine trials among all newoutpatient antipsychotic trials increased 40% among adult New York Medicaid recipients with a diagnosis of schizophrenia. The largest gains occurred in state-operated clinics. New York's experience demonstrates the feasibility of making clozapine more accessible to patients who stand to benefit most.

UR - http://www.scopus.com/inward/record.url?scp=84989883983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989883983&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.201500493

DO - 10.1176/appi.ps.201500493

M3 - Article

VL - 67

SP - 369

EP - 371

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 4

ER -